BR112021024314A2 - Composições e métodos anti-siglec-9 para modular fenótipos inflamatórios de células mieloides e usos dos mesmos - Google Patents
Composições e métodos anti-siglec-9 para modular fenótipos inflamatórios de células mieloides e usos dos mesmosInfo
- Publication number
- BR112021024314A2 BR112021024314A2 BR112021024314A BR112021024314A BR112021024314A2 BR 112021024314 A2 BR112021024314 A2 BR 112021024314A2 BR 112021024314 A BR112021024314 A BR 112021024314A BR 112021024314 A BR112021024314 A BR 112021024314A BR 112021024314 A2 BR112021024314 A2 BR 112021024314A2
- Authority
- BR
- Brazil
- Prior art keywords
- siglec
- compositions
- methods
- myeloid cell
- cell phenotypes
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 230000002757 inflammatory effect Effects 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 210000000066 myeloid cell Anatomy 0.000 title abstract 3
- 230000004913 activation Effects 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 210000004443 dendritic cell Anatomy 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 210000002540 macrophage Anatomy 0.000 abstract 1
- 210000001616 monocyte Anatomy 0.000 abstract 1
- 210000004479 myeloid suppressor cell Anatomy 0.000 abstract 1
- 210000000440 neutrophil Anatomy 0.000 abstract 1
- 230000010287 polarization Effects 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4614—Monocytes; Macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2301—Interleukin-1 (IL-1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2306—Interleukin-6 (IL-6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/25—Tumour necrosing factors [TNF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
Abstract
composições e métodos anti-siglec-9 para modular fenótipos inflamatórios de células mieloides e usos dos mesmos. a presente invenção é baseada, em parte, na descoberta de composição anti-siglec-9 (por exemplo, anticorpos monoclonais e fragmentos de ligação ao antígeno dos mesmos), que regula fenótipos inflamatórios de células mieloides, tais como células mieloides supressoras, monócitos, macrófagos, neutrófilos e/ou células dendríticas, incluindo polarização, ativação e/ou função e métodos de usar essas composições anti-siglec-9 para propósitos terapêuticos, diagnósticos, prognósticos e de triagem.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962857194P | 2019-06-04 | 2019-06-04 | |
US201962867577P | 2019-06-27 | 2019-06-27 | |
US202063032292P | 2020-05-29 | 2020-05-29 | |
PCT/US2020/035703 WO2020247372A1 (en) | 2019-06-04 | 2020-06-02 | Anti-siglec-9 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112021024314A2 true BR112021024314A2 (pt) | 2022-02-15 |
Family
ID=73653315
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112021024314A BR112021024314A2 (pt) | 2019-06-04 | 2020-06-02 | Composições e métodos anti-siglec-9 para modular fenótipos inflamatórios de células mieloides e usos dos mesmos |
Country Status (11)
Country | Link |
---|---|
US (1) | US20220396627A1 (pt) |
EP (1) | EP3980462A4 (pt) |
JP (1) | JP2022535417A (pt) |
KR (1) | KR20220042056A (pt) |
CN (1) | CN114401991A (pt) |
AU (1) | AU2020288824A1 (pt) |
BR (1) | BR112021024314A2 (pt) |
CA (1) | CA3142433A1 (pt) |
IL (1) | IL288511A (pt) |
TW (1) | TW202110890A (pt) |
WO (1) | WO2020247372A1 (pt) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202132329A (zh) | 2019-11-04 | 2021-09-01 | 美商阿列克特有限責任公司 | Siglec-9 ecd融合分子及其使用方法 |
AU2021329884A1 (en) * | 2020-08-17 | 2023-02-16 | SURGE Therapeutics, Inc. | Immune modulation of myeloid derived suppressive cell function for cancer treatment |
WO2023192993A2 (en) * | 2022-03-31 | 2023-10-05 | The Wistar Institute Of Anatomy And Biology | Antibodies against human siglec-7 and use thereof for immunotherapy |
WO2023192990A2 (en) * | 2022-03-31 | 2023-10-05 | The Wistar Institute Of Anatomy And Biology | Antibodies against human siglec-9 and use thereof for immunotherapy |
WO2024054527A1 (en) * | 2022-09-06 | 2024-03-14 | The Research Institute At Nationwide Children's Hospital | Genetically engineered bone marrow derived myeloid cells for treatment of central nervous system tumors |
CN116380755B (zh) * | 2023-03-20 | 2023-11-21 | 广州市第一人民医院(广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院) | CD127+PMN-MDSCs在诊断支气管肺发育不良中的应用及诊断试剂盒 |
CN117741143B (zh) * | 2024-02-20 | 2024-05-07 | 首都医科大学附属北京地坛医院 | Siglec-9蛋白及其特异性抗体在制备神经梅毒或神经损伤诊断产品中的应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0521991D0 (en) * | 2005-10-28 | 2005-12-07 | Univ Dundee | Siglec-9 binding agents |
SG11201803567XA (en) * | 2015-10-29 | 2018-05-30 | Alector Llc | Anti-siglec-9 antibodies and methods of use thereof |
EP3402516A4 (en) * | 2016-01-12 | 2020-01-08 | Palleon Pharmaceuticals Inc. | USE OF ANTIBODIES DIRECTED AGAINST SIGLEC-7 OR SIGLEC-9 IN THE TREATMENT OF CANCER |
GB201611535D0 (en) * | 2016-07-01 | 2016-08-17 | King's College London | Methods and compositions for treating cancer with siglec-9 activity modulators |
CN111263769B (zh) * | 2017-07-10 | 2024-01-02 | 先天制药公司 | Siglec-9中和性抗体 |
-
2020
- 2020-06-02 WO PCT/US2020/035703 patent/WO2020247372A1/en unknown
- 2020-06-02 US US17/615,861 patent/US20220396627A1/en active Pending
- 2020-06-02 CA CA3142433A patent/CA3142433A1/en active Pending
- 2020-06-02 BR BR112021024314A patent/BR112021024314A2/pt unknown
- 2020-06-02 AU AU2020288824A patent/AU2020288824A1/en not_active Abandoned
- 2020-06-02 KR KR1020217040139A patent/KR20220042056A/ko unknown
- 2020-06-02 TW TW109118528A patent/TW202110890A/zh unknown
- 2020-06-02 EP EP20818538.9A patent/EP3980462A4/en active Pending
- 2020-06-02 JP JP2021571944A patent/JP2022535417A/ja active Pending
- 2020-06-02 CN CN202080056075.5A patent/CN114401991A/zh active Pending
-
2021
- 2021-11-29 IL IL288511A patent/IL288511A/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP3980462A4 (en) | 2023-09-20 |
CA3142433A1 (en) | 2020-12-10 |
JP2022535417A (ja) | 2022-08-08 |
WO2020247372A1 (en) | 2020-12-10 |
IL288511A (en) | 2022-01-01 |
TW202110890A (zh) | 2021-03-16 |
EP3980462A1 (en) | 2022-04-13 |
CN114401991A (zh) | 2022-04-26 |
US20220396627A1 (en) | 2022-12-15 |
KR20220042056A (ko) | 2022-04-04 |
AU2020288824A1 (en) | 2022-02-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112021024314A2 (pt) | Composições e métodos anti-siglec-9 para modular fenótipos inflamatórios de células mieloides e usos dos mesmos | |
BR112022023892A2 (pt) | Composições anti-vsig4 e métodos para modular fenótipos inflamatórios de células mieloides e seus usos | |
BR112019001570A2 (pt) | terapias de combinação de receptores de antígeno quiméricos e inibidores de pd-1 | |
Ickowicz et al. | Mechanism of sperm capacitation and the acrosome reaction: role of protein kinases | |
Schlecker et al. | Metalloprotease-mediated tumor cell shedding of B7-H6, the ligand of the natural killer cell–activating receptor NKp30 | |
BR112018070636A2 (pt) | método de tratamento de um sujeito humano que tem câncer, anticorpo, uso de um anticorpo, anticorpo para uso, combinação de um anticorpo, kit para uso no tratamento de câncer, composição farmacêutica, anticorpo biespecífico, método para tratamento de câncer, anticorpo biespecífico para uso e método de depleção de células t reguladoras em um tumor sólido em um sujeito | |
BR112021024242A2 (pt) | Composições e métodos anti-psgl-1 para modular fenótipos inflamatórios de células mieloides e usos dos mesmos | |
Moon et al. | Diet-induced hypercholesterolemia promotes androgen-independent prostate cancer metastasis via IQGAP1 and caveolin-1 | |
WO2018011631A3 (en) | ULTRASONIC FOCUSING BASED ON PRECESSION | |
BR112018000768A2 (pt) | anticorpos anti-pd-1, anticorpos anti-pd-1 ativáveis e métodos de uso dos mesmos | |
MX2021005353A (es) | Composiciones, metodos y sistemas para el analisis de la corona proteica y usos de los mismos. | |
EA202092825A1 (ru) | Анти-sirpa антитела и способы их применения | |
BR112021026411A2 (pt) | Composições anti-lrrc25 e métodos para modular fenótipos inflamatórios de células mieloides e usos dos mesmos | |
BR112021026181A2 (pt) | Composições anti-cd53 e métodos para modular fenótipos inflamatórios de células mieloides e usos dos mesmos | |
BR112017014551A2 (pt) | ?anticorpo, construção de ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos para tratamento de uma doença, para produção de um anticorpo biespecífico e para detecção da possível ocorrência de reticulação entre células com expressão de cd3 e cd20 em uma amostra derivada de um paciente, uso de um anticorpo biespecífico, e, kit? | |
BR112015006060A2 (pt) | agentes de ligação kir3dl2 | |
WO2018115017A3 (en) | CRYSTALLINE STRUCTURE OF GREMLIN-1 AND ANTIBODY INHIBITOR | |
BR112014010532A2 (pt) | anticorpo e métodos para inibição seletiva de respostas de célula-t | |
MA38828A1 (fr) | Anticorps dirigés contre l'inhibiteur des activateurs du plasminogène de type 1 (pai-1) et leurs utilisations | |
IN2014DN08064A (pt) | ||
BR112013027631A2 (pt) | Método para a produção de anticorpo monoclonal ou fragmento que inclui uma região de ligação ao antígeno do mesmo, anticorpo monoclonal ou um fragmento que inclui uma região de 5 ligação ao antígeno do mesmo, hibridoma, método para a detecção de uma célula dendrítica plasmocitóide, uso de um anticorpo monoclonal ou um fragmento que inclui uma região de ligação ao antígeno do mesmo, e método ex vivo para suprimir a atividade de uma célula dendrítica plasmocitóide | |
TR201910410T4 (tr) | Endometriyal patolojilerde kök hücre terapisi. | |
BR112021015056A2 (pt) | Inibidores específicos de complexos ltbp de tgf-beta e usos dos mesmos | |
EA202090527A1 (ru) | Модифицированный car-t | |
PH12020550117A1 (en) | Variant rnai |